A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

Item
http://www.wikidata.org/entity/Q33267207
Prostate cancer epigenetics and its clinical implicationsUsing routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme.Indirect comparisons: a review of reporting and methodological qualityDrug costs in the management of metastatic castration-resistant prostate cancer in Canada.Racial variation in the cost-effectiveness of chemotherapy for prostate cancer.The role of chemotherapy at the end of life: "when is enough, enough?".Development of drug delivery systems based on layered hydroxides for nanomedicine.When to wait for more evidence? Real options analysis in proton therapy.Using systematic reviews to inform NIHR HTA trial planning and design: a retrospective cohort.A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancerA systematic and critical review of the evolving methods and applications of value of information in academia and practice.Pain in castration-resistant prostate cancer with bone metastases: a qualitative study.What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?Continuous time simulation and discretized models for cost-effectiveness analysis.Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression.Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer
P2860

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

Item
http://www.wikidata.org/entity/Q33267207
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A systematic review and econom ...... ry metastatic prostate cancer.
@ast
A systematic review and econom ...... ry metastatic prostate cancer.
@en
A systematic review and econom ...... ry metastatic prostate cancer.
@nl
type
label
A systematic review and econom ...... ry metastatic prostate cancer.
@ast
A systematic review and econom ...... ry metastatic prostate cancer.
@en
A systematic review and econom ...... ry metastatic prostate cancer.
@nl
prefLabel
A systematic review and econom ...... ry metastatic prostate cancer.
@ast
A systematic review and econom ...... ry metastatic prostate cancer.
@en
A systematic review and econom ...... ry metastatic prostate cancer.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
A systematic review and econom ...... ory metastatic prostate cancer
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698